On November 20, 2007, Swiss-based drug discovery informatics provider Genedata AG announced the establishment of a novel research IT alliance with Nycomed, a global leader in innovative pharmaceuticals.
An increasing number of pharmaceutical companies are outsourcing their research IT services to specialized partners in order to increase focus on their core competencies, drive IT innovation and subsequently improve IT performance and reduce overall R&D costs. In line with this trend and Nycomed`s new R&D operating model, Genedata and Nycomed are establishing a strategic partnership that will capitalize on Genedata`s extensive technological expertise to support Nycomed`s proprietary R&D data and knowledge management.
The existing Nycomed research IT infrastructure will be adapted to the new R&D operating model, with Genedata supporting Nycomed in developing and implementing scientific databases and applications for research data management and scientific analysis. The implementation of novel solutions and more efficient workflows is key in this effort. To enhance the smooth integration of Genedata’s expertise into the R&D operations of Nycomed, Genedata has established an office on location, at the Nycomed site in Konstanz, Germany.
“Our new R&D strategy and operating model is aiming for a highly flexible organization that focuses on its core competencies to fill our pipeline with medicines that have true medical utility. For this we were seeking an outsourcing partner able to provide superior technology as well as expertise, and launch quality solutions in a short span of time,“ explained Dr. Karl Zech, Senior Vice President Discovery and Proof of Concept Development at Nycomed. “In addition, effective partnering requires an established, trusting and highly interactive relationship, which makes Genedata a distinguished first choice.”
Dr. Othmar Pfannes, CEO of Genedata AG, said: “We are delighted and committed to take a prolific long-term collaboration to an even higher level, supporting Nycomed to leverage in-house resources and gain competitive advantage. Taking on operational responsibilities represents a new Genedata business approach, that, in complexity and scope, goes beyond the customary provision of software products and services.”
Nycomed is a pharmaceutical company that provides medicines for hospitals, specialists and general practitioners, as well as over-the-counter medicines in selected markets. The company is active within a range of therapeutic areas, including cardiology, gastroenterology, osteoporosis, respiratory, pain and tissue management. New products are sourced both from own research and from external partners. Operating throughout Europe and in fast-growing markets such as Latin America, Russia/CIS and the Asia-Pacific region Nycomed has a presence in about 50 markets worldwide. Privately owned, the combined group had annual sales of approximately € 3.4 billion and an EBITDA of € 933.4 million (2006 results). For more information visit www.nycomed.com.
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery, industrial biotechnology, and life science research. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata solutions make research data accessible and understandable, enabling scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Japan, Germany, and the US. www.genedata.com
Marketing & Communications
Phone: +41 61 511 8459
Phone: +1 508 881 3109
Dr. Martin Zoche
Senior Project Manager, Support & Operations
Phone: +49 7531 84 4506
Fax: +49 7531 849 4506
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.